Loading
imRECIST is a variant of the scan-measuring rules from atezolizumab trials that lets a response after apparent growth count, to capture benefit from immunotherapy that standard rules miss.
Hodi and colleagues (Journal of Clinical Oncology 2018) applied immune-modified RECIST to atezolizumab trial data in lung, bladder and kidney cancer and melanoma. It allows a best response after progressive disease and changes how new and non-target lesions define progression. Compared with RECIST 1.1, best overall response was 1 to 2 percentage points higher, disease control 8 to 13 points higher and median progression-free survival 0.5 to 1.5 months longer. Progression defined only by new lesions was not associated with longer survival.
Showing the technology this term belongs to: Immune checkpoint inhibitors.
Shares iRECIST (response criteria for immunotherapy trials), RECIST.
Shares iRECIST (response criteria for immunotherapy trials), Immune checkpoint inhibitors.
Shares iRECIST (response criteria for immunotherapy trials), Immune checkpoint inhibitors.
Shares iRECIST (response criteria for immunotherapy trials), RECIST.
Shares RECIST, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/